Skip to content

Study · Measured the body's own peptide · 2001

3 results

Arginine-vasopressin and oxytocin response to cholecystokinin-tetrapeptide.

Le Mellédo JM, Bradwejn J, Koszycki D, Bellavance F, Bichet D

Peptides1 Aug 2001Cited by 13 (Europe PMC)

PMID11457531 (opens in a new tab)DOI10.1016/s0196-9781(01)00462-4 (opens in a new tab)PepBankPUB-11457531
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelNon-randomized trialOther

    In women with premenstrual dysphoric disorder and control women, intravenous CCK-4 increased plasma oxytocin concentrations.

    In plain wordsIn women with and without PMDD, CCK-4 raised the body's own oxytocin levels in blood.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin after CCK-4
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Plasma AVP and OT concentrations increased following CCK-4 administration.
    1 context sentence
    Summary · context
    This study examined the effects of i.v. administration of cholecystokinin-tetrapeptide (CCK-4) on plasma release of arginine vasopressin (AVP) and oxytocin (OT) in women with premenstrual dysphoric disorder (PMDD) and control women, during both the follicular phase and the luteal phase of their menstrual cycle.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelNon-randomized trialOther

    The plasma oxytocin response to CCK-4 was similar in women with PMDD and control women.

    In plain wordsThe rise in the body's own oxytocin after CCK-4 was similar in women with PMDD and in control women.

    Peptide
    Oxytocin
    Outcome
    No significant changeOxytocin response to CCK-4, PMDD versus controls
    Study

    n: not reported in source

    Comparator
    Control women
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    AVP and OT response to CCK-4 was similar for PMDD and control women
    1 context sentence
    Summary · context
    This study examined the effects of i.v. administration of cholecystokinin-tetrapeptide (CCK-4) on plasma release of arginine vasopressin (AVP) and oxytocin (OT) in women with premenstrual dysphoric disorder (PMDD) and control women, during both the follicular phase and the luteal phase of their menstrual cycle.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelNon-randomized trialOther

    The plasma oxytocin response to CCK-4 was unaffected by menstrual cycle phase.

    In plain wordsThe rise in the body's own oxytocin after CCK-4 did not differ between phases of the menstrual cycle.

    Peptide
    Oxytocin
    Outcome
    No significant changeOxytocin response to CCK-4 by menstrual cycle phase
    Study

    n: not reported in source

    Comparator
    Follicular versus luteal phase
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    unaffected by menstrual cycle phase.
    1 context sentence
    Summary · context
    This study examined the effects of i.v. administration of cholecystokinin-tetrapeptide (CCK-4) on plasma release of arginine vasopressin (AVP) and oxytocin (OT) in women with premenstrual dysphoric disorder (PMDD) and control women, during both the follicular phase and the luteal phase of their menstrual cycle.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:51 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.